Contacts:Investor Relations John Graziano1firstname.lastname@example.orgMedia Relations Lindsay Rocco1email@example.com
BOULDER, Colo., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference and the Stifel 2016 Healthcare Conference. Details of the two presentations are as follows: 25th Annual Credit Suisse Healthcare Conference Date: Tuesday, November 8 th Location: The Phoenician, ArizonaPresentation Time: 4:00 PM MST Stifel 2016 Healthcare Conference Date: Tuesday, November 15 th Location: The Lotte New York Palace Hotel, New YorkPresentation Time: 10:15 AM EST Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section. A replay of the webcast will be available on this site for 90 days following the live event. About Nivalis Therapeutics, Inc. Nivalis Therapeutics, Inc. ( http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.